| Title | Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. | | Author(s) | Pearson T, Ballantyne C, Sisk C, Shah A, Veltri E, Maccubbin D | | Institution | University of Rochester School of Medicine and Dentistry, Rochester, New York, USA. thomas_pearson@urmc.rochester.edu | | Source | Am J Cardiol 2007 Jun 15; 99(12):1706-1713. | | MeSH | Adult
Aged
Anticholesteremic Agents
Azetidines
C-Reactive Protein
Cholesterol, LDL
Double-Blind Method
Drug Combinations
Female
Heptanoic Acids
Humans
Hypercholesterolemia
Male
Middle Aged
Pyrroles
Randomized Controlled Trials as Topic
Simvastatin
| | Abstract | The lowering effects of ezetimibe/simvastatin combination therapy on low-density lipoprotein (LDL) cholesterol and high-sensitivity C-reactive protein (CRP) were compared with those of simvastatin or atorvastatin monotherapy in a large cohort of patients with primary hypercholesterolemia. To compare ezetimibe/simvastatin with simvastatin, data were combined from 3 identical, prospective 12-week trials in which patients were randomized to receive placebo; ezetimibe 10 mg; ezetimibe 10 mg added to simvastatin 10, 20, 40, or 80 mg; or simvastatin 10, 20, 40, or 80 mg. To compare ezetimibe/simvastatin with atorvastatin, data were analyzed from a phase III double-blind, active-controlled study in which patients were randomized equally to receive ezetimibe/simvastatin 10/10, 10/20, 10/40, or 10/80 mg or atorvastatin 10, 20, 40, or 80 mg for 6 weeks. When averaged across doses, ezetimibe/simvastatin produced significantly greater reductions compared with simvastatin alone in LDL cholesterol (52.5% vs 38.0%, respectively) and CRP levels (31.0% vs 14.3%, respectively). At each individual simvastatin dose, co-administration with ezetimibe produced significant further CRP reductions versus simvastatin alone. Ezetimibe/simvastatin was significantly more effective at lowering LDL cholesterol than atorvastatin when pooled across doses (53.4% vs 45.3%, respectively) and in each milligram-equivalent dose comparison. Reductions in CRP of similar magnitude were observed with ezetimibe/simvastatin and atorvastatin when averaged across doses and at each milligram-equivalent statin dose comparison. In conclusion, the lipid-modulating and anti-inflammatory effects of ezetimibe/simvastatin provide additional benefits not realized by statin monotherapy alone. | | Language | eng | | Pub Type(s) | Comparative Study
Journal Article
Meta-Analysis
| | PubMed ID | 17560879 |
|
